Phaseline

Targets › KLK2

KLK2 (Kallikrein-2): drug programs, companies and trials

2 programs from 1 company in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.

Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. (UniProt, P20151)

Open in Phaseline: the race on KLK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Johnson & Johnson (Janssen)JNJ-69086420
Actinium-225-labeled anti-hK2 antibody (alpha-particle emitting radiopharmaceutical)
KLK2Phase 1Prostatic NeoplasmsDec 2026
Johnson & Johnson (Janssen)JNJ-78278343
KLK2-CD3 bispecific antibody (pasritamig)
KLK2, CD3EPhase 1Prostatic NeoplasmsDec 2026

Conditions

Prostatic Neoplasms (5)

Modalities

mixed (1), small molecule (1)

Companies

Johnson & Johnson (Janssen) (2)

Related targets

CD3E (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.